• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FTT
Click for more information
0.00% 0.5¢

FACTOR THERAPEUTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
FTT Change in substantial holding09/10/17
FTT Shareholder communication - clinical trial updatePRICE SENSITIVE05/10/17
FTT CEO Presentation to Broker Meets Biotech07/09/17
FTT Appendix 3B - issue of unlisted share options21/08/17
FTT Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE15/08/17
FTT Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
FTT Change in substantial holding26/07/17
FTT Ocular Wound Care Program Update17/07/17
FTT Clinical Trial Update10/07/17
FTT Shareholder Newsletter Q2 201706/07/17
FTT Change in substantial holding05/07/17
FTT Change in substantial holding05/07/17
FTT Appendix 3B - unlisted share options issued to CEO23/06/17
FTT Investor Presentation - June 201713/06/17
FTT Change in substantial holding30/05/17
FTT Dr. Christian Behrenbruch transitions to NED22/05/17
FTT Appointment of Dr. Rosalind Wilson as CEOPRICE SENSITIVE22/05/17
FTT Becoming a substantial holder15/05/17
FTT Appendix 4CPRICE SENSITIVE27/04/17
FTT Phase II clinical trial progress updatePRICE SENSITIVE07/04/17
FTT Shareholder Update - Q1 201703/04/17
FTT Half Year AccountsPRICE SENSITIVE15/02/17
FTT Initial Director's Interest Notice - John Michailidis14/02/17
FTT Appointment of John Michailidis as Non-Executive Director14/02/17
FTT Unmarketable parcel sale facility13/02/17
FTT Appendix 4C - December 2016 quarterPRICE SENSITIVE24/01/17
FTT Biotech Showcase Presentation11/01/17
FTT Phase II Clinical Trial - First Patient InPRICE SENSITIVE20/12/16
FTT Appendix 3Y - Mr Tim Hughes (correction)23/11/16
FTT Appendix 3Y - Dr Chris Behrenbruch (correction)23/11/16
FTT Appendix 3Y - Dr Cherrell Hirst (correction)23/11/16
FTT Appendix 3Y - Dr Robert Ryan (options)23/11/16
FTT Appendix 3B - unlisted share options following AGM23/11/16
FTT Constitution of Factor Therapeutics Limited23/11/16
FTT AGM Results of Meeting23/11/16
FTT Executive Team presentation to AGM23/11/16
FTT Chairman's Address to AGM23/11/16
FTT Collaboration and IP option agreement with Monash UniversityPRICE SENSITIVE22/11/16
FTT Investor Update22/11/16
FTT Human Capital Update21/11/16
FTT VF001 - Clinical Presentation09/11/16
FTT Notification of Investor Conference Call07/11/16
FTT FDA - lift of clincial holdPRICE SENSITIVE07/11/16
FTT Edison initiates research coverage-FTT.AX 31/10/16
FTT Appendix 4C for the September Quarter-FTT.AX PRICE SENSITIVE27/10/16
FTT Annual Report to Shareholders-FTT.AX 24/10/16
FTT Corporate Governance Statement-FTT.AX 24/10/16
FTT Appendix 4G - key to corporate governance disclosures-FTT.AX 24/10/16
FTT AGM Notice of Meeting, Proxy and Proposed Constitution-FTT.AX 21/10/16
FTT Submission of IND amendments for Phase II study-FTT.AX PRICE SENSITIVE10/10/16
FTT Shareholder Update-FTT.AX 04/10/16
FTT Change of Registered Address-FTT.AX 29/09/16
FTT Company Secretary Appointment-FTT.AX 29/09/16
FTT Initial Director's Interest Notice-FTT.AX 14/09/16
FTT Director Appointment-FTT.AX 14/09/16
FTT Completion of Manufacturing-FTT.AX PRICE SENSITIVE09/09/16
FTT Appendix 3B-FTT.AX 24/08/16
FTT Financial Report YE 30 June 2016-FTT.AX 17/08/16
FTT Appendix 4E - Preliminary Final Report-FTT.AX PRICE SENSITIVE17/08/16
FTT Appendix 3B-FTT.AX 03/08/16
FTT Formation of Medical Advisory Board-FTT.AX PRICE SENSITIVE03/08/16
FTT Appendix 4C - quarterly-FTT.AX PRICE SENSITIVE28/07/16
FTT Change of Director's Interest Notice - C Behrenbruch-FTT.AX 26/07/16
FTT Change of Director's Interest Notice - C Hirst-FTT.AX 26/07/16
FTT Appendix 3B-FTT.AX 26/07/16
FTT Cleansing notice s708A(5)(e)-FTT.AX 26/07/16
FTT Appendix 3B-FTT.AX 01/07/16
FTT Results of Meeting-FTT.AX 29/06/16
FTT Clinical Trial Update-FTT.AX PRICE SENSITIVE15/06/16
FTT Shareholder Update-FTT.AX 17/05/16
FTT Change in substantial holding
09/10/17
FTT Shareholder communication - clinical trial update
05/10/17PRICE SENSITIVE
FTT CEO Presentation to Broker Meets Biotech
07/09/17
FTT Appendix 3B - issue of unlisted share options
21/08/17
FTT Appendix 4E and Full Year Statutory Accounts
15/08/17PRICE SENSITIVE
FTT Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
FTT Change in substantial holding
26/07/17
FTT Ocular Wound Care Program Update
17/07/17
FTT Clinical Trial Update
10/07/17
FTT Shareholder Newsletter Q2 2017
06/07/17
FTT Change in substantial holding
05/07/17
FTT Change in substantial holding
05/07/17
FTT Appendix 3B - unlisted share options issued to CEO
23/06/17
FTT Investor Presentation - June 2017
13/06/17
FTT Change in substantial holding
30/05/17
FTT Dr. Christian Behrenbruch transitions to NED
22/05/17
FTT Appointment of Dr. Rosalind Wilson as CEO
22/05/17PRICE SENSITIVE
FTT Becoming a substantial holder
15/05/17
FTT Appendix 4C
27/04/17PRICE SENSITIVE
FTT Phase II clinical trial progress update
07/04/17PRICE SENSITIVE
FTT Shareholder Update - Q1 2017
03/04/17
FTT Half Year Accounts
15/02/17PRICE SENSITIVE
FTT Initial Director's Interest Notice - John Michailidis
14/02/17
FTT Appointment of John Michailidis as Non-Executive Director
14/02/17
FTT Unmarketable parcel sale facility
13/02/17
FTT Appendix 4C - December 2016 quarter
24/01/17PRICE SENSITIVE
FTT Biotech Showcase Presentation
11/01/17
FTT Phase II Clinical Trial - First Patient In
20/12/16PRICE SENSITIVE
FTT Appendix 3Y - Mr Tim Hughes (correction)
23/11/16
FTT Appendix 3Y - Dr Chris Behrenbruch (correction)
23/11/16
FTT Appendix 3Y - Dr Cherrell Hirst (correction)
23/11/16
FTT Appendix 3Y - Dr Robert Ryan (options)
23/11/16
FTT Appendix 3B - unlisted share options following AGM
23/11/16
FTT Constitution of Factor Therapeutics Limited
23/11/16
FTT AGM Results of Meeting
23/11/16
FTT Executive Team presentation to AGM
23/11/16
FTT Chairman's Address to AGM
23/11/16
FTT Collaboration and IP option agreement with Monash University
22/11/16PRICE SENSITIVE
FTT Investor Update
22/11/16
FTT Human Capital Update
21/11/16
FTT VF001 - Clinical Presentation
09/11/16
FTT Notification of Investor Conference Call
07/11/16
FTT FDA - lift of clincial hold
07/11/16PRICE SENSITIVE
FTT Edison initiates research coverage-FTT.AX
31/10/16
FTT Appendix 4C for the September Quarter-FTT.AX
27/10/16PRICE SENSITIVE
FTT Annual Report to Shareholders-FTT.AX
24/10/16
FTT Corporate Governance Statement-FTT.AX
24/10/16
FTT Appendix 4G - key to corporate governance disclosures-FTT.AX
24/10/16
FTT AGM Notice of Meeting, Proxy and Proposed Constitution-FTT.AX
21/10/16
FTT Submission of IND amendments for Phase II study-FTT.AX
10/10/16PRICE SENSITIVE
FTT Shareholder Update-FTT.AX
04/10/16
FTT Change of Registered Address-FTT.AX
29/09/16
FTT Company Secretary Appointment-FTT.AX
29/09/16
FTT Initial Director's Interest Notice-FTT.AX
14/09/16
FTT Director Appointment-FTT.AX
14/09/16
FTT Completion of Manufacturing-FTT.AX
09/09/16PRICE SENSITIVE
FTT Appendix 3B-FTT.AX
24/08/16
FTT Financial Report YE 30 June 2016-FTT.AX
17/08/16
FTT Appendix 4E - Preliminary Final Report-FTT.AX
17/08/16PRICE SENSITIVE
FTT Appendix 3B-FTT.AX
03/08/16
FTT Formation of Medical Advisory Board-FTT.AX
03/08/16PRICE SENSITIVE
FTT Appendix 4C - quarterly-FTT.AX
28/07/16PRICE SENSITIVE
FTT Change of Director's Interest Notice - C Behrenbruch-FTT.AX
26/07/16
FTT Change of Director's Interest Notice - C Hirst-FTT.AX
26/07/16
FTT Appendix 3B-FTT.AX
26/07/16
FTT Cleansing notice s708A(5)(e)-FTT.AX
26/07/16
FTT Appendix 3B-FTT.AX
01/07/16
FTT Results of Meeting-FTT.AX
29/06/16
FTT Clinical Trial Update-FTT.AX
15/06/16PRICE SENSITIVE
FTT Shareholder Update-FTT.AX
17/05/16
refresh Created with Sketch. REFRESH
 

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals Pro Medicus Ltd is set to roll out a suite of diagnostic imaging products across the health care system run by Trinity Health
Australian Rare Earths bullish on early-stage uranium potential at Overland, SA Australian Rare Earths has asserted it's set to launch follow up drilling after aircore results show potential uranium downhole at Overland.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Chimeric clocks $4.17M R&D tax rebate from Canberra Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.